Since July 2025, her treatment has been carried out at Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), Delhi, following internationally accepted clinical protocols. To date, she has successfully completed multiple critical phases of treatment, including:

With radiation therapy concluded, the medical team is currently planning and preparing for the next consolidation phase — Immunotherapy, which is scheduled to commence in March 2026. This phase is clinically significant in reducing the probability of relapse and improving long-term survival outcomes in high-risk pediatric neuroblastoma cases.

As per the hospital’s officially issued estimate certificate, the cost of the immunotherapy phase is approximately ₹75–85 lakhs. The cost is primarily attributable to the requirement of imported, specialized medicines that are not manufactured in India.

The treatment journey thus far has been managed through personal resources and support from well-wishers. As we approach this advanced and essential phase of care, we are extending this campaign to seek structured and shared support to meet the remaining treatment expenses.

Contributions toward this cause will directly support the timely administration of immunotherapy, ensuring continuity of care in accordance with the prescribed medical protocol. Support through dissemination of this campaign within professional or organizational networks is also highly valued.

Thank you for your consideration and support.

Warm regards,

Harsh Vardhan Jain